Clinical Trials Logo

Pneumococcal Vaccines clinical trials

View clinical trials related to Pneumococcal Vaccines.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06151288 Active, not recruiting - Clinical trials for Pneumococcal Vaccines

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Start date: November 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.

NCT ID: NCT06077656 Active, not recruiting - Clinical trials for Pneumococcal Vaccines

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Start date: October 25, 2023
Phase: Phase 2
Study type: Interventional

Phase 2 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)

NCT ID: NCT05844423 Active, not recruiting - Clinical trials for Pneumococcal Vaccines

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Start date: March 29, 2023
Phase: Phase 2
Study type: Interventional

The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.

NCT ID: NCT02012309 Active, not recruiting - HIV Clinical Trials

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Start date: August 2014
Phase: N/A
Study type: Interventional

Human Immunodeficiency Virus (HIV) infection is complicated by high rates of infections and cancers which are often the cause of death rather than the HIV/acquired immune deficiency syndrome (AIDS) virus itself. Treatment of HIV with antiretroviral medications has decreased the frequency of many complications by over 90%, but bacterial pneumonia remains extremely high. Current vaccines are not very effective in preventing these infections in patients with HIV infection. The investigators are studying the cells (B cells) that make antibodies to fight infection by binding to and killing bacteria. The goal is to understand how HIV impairs the ability of B cells to make antibodies in sufficient quantity and of sufficient quality to protect patients with HIV to learn how to enhance protection against these infections. The investigators also seek to understand the role of the bacteria (specifically Streptococcus pneumoniae) that normally live in the nose and throat in the development of pneumonia and other infections.